Search

J.A. Arranz Arija, B. Perez-Valderrama, J.L. Gonzalez-Larriba, A. Rodriguez Sanchez, I. Chirivella, A. Pinto, R.D. Garcia Marrero, G. Rubio, J.M. Jurado Garcia, P. Borrega, M. Lazaro Quintela, D.E. Castellano, C. Suarez Rodriguez, J.A. Meana Garcia, J.J. Lambea-Sorrosal, P. Gajate, M.J. Juan Fita, J.L. Puertas, R. Garcia Dominguez, J.C. Villa Guzman. Hospital General universitario Gregorio Maranon, Medical Oncology Service, Madrid, Spain; Hospitales Universitarios Virgen del Rocio, Medical Oncology Service, Seville, Spain; Hospital Clinico San Carlos, Medical Oncology Service, Madrid, Spain; Hospital Universitario de Leon, Medical Oncology Service, Leon, Spain; Hospital Clinico Universitario, Medical oncology Service, Valencia, Spain; Hospital Universitario La Paz, Medical Oncology Service, Madrid, Spain; Hospital Universitario de Canarias, Medical Oncology Service, Santa Cruz de Tenerife, Spain; Hospital Universitario Fundacion Jimenez Diaz, Medical Oncology Service, Madrid, Spain; Hospital Universitario San Cecilio, Medical Oncology Service, Granada, Spain; Hospital San Pedro de Alcantara, Medical Oncology Service, Caceres, Spain; Complexo Hospitalario Universitario de Vigo, Medical Oncology Service, Vigo, Spain; Hospital Universitario 12 de Octubre, Medical Oncology Service, Madrid, Spain; Hospital Universitari Vall d’Hebron, Medical Oncology Service, Barcelona, Spain; Hospital General Universitario de Alicante, Medical Oncology Service, Alicante, Spain; Hospital Universitario Lozano Blesa, Medical Oncology Service, Zaragoza, Spain; Hospital Universitario Quiron, Medical Oncology Service, Madrid, Spain; 17 Instituto Valenciano de Oncologia IVO, Medical Oncology Service, Valencia, Spain; Hospital Universitario Rio Hortega, Medical Oncology Service, Valladolid, Spain; Hospital Universitario de Salamanca, Medical Oncology Service, Salamanca, Spain; Hospital General Universitario de Ciudad Real, Medical Oncology Service, Ciudad Real, Spain

e15597 Background: The IMRCC prognostic model for mRCC treated with VEGF-targeted agents (Heng, JCO '09) has been externally validated (Heng, Lancet Oncol '13), however, pt treated with Pz were not...

e15609 Background: In clinical trials pazopanib (P) was superior to placebo, noninferior to sunitinib, and very well tolerated as 1st-line for mRC, but there is limited information in daily clinical practice. Methods: We retrospectively reviewed 159 patients (p) who received P in in 31 centers in Spain during the first 18 month after P approval, to evaluate the timing of use and its efficacy. Results: Mean age was 66 y, 64.8% were males, 81.1% clear-cell, 12% non-clear cell, and 6.9% unspecified. At diagnosis of mRC 73.6% had nephrectomy, 78.6% and 71.7% of p were of good-intermediate risk (MSKCC and Heng criteria respectively). Metastatic sites were lung (59.7%), lymph nodes (26.4%), bone (22.6%), skin/soft-tissues (17.6%), liver (11.9%), CNS (2.5%), and 31.4% others (adrenal, pancreas, etc.). Median follow-up since diagnosis of mRC was 16 months (m). P was given as 1st systemic treatment in 81 p, (50.9%), as 2nd line in 32 p (20.1%, most after sunitinib, 17 due to intolerance), or as ≥3r line (46 p, 29%). Median follow-up after P was 7 m in 1st line, and 10 m in 2nd or ≥ 3rd line. Toxicity was as expected. No toxic deaths were registered. At the time of analysis, 85 p have discontinued P (progression: 73 p, toxicity: 10 p, other causes: 2 p), and 35 p have died. The table shows time to treatment failure due to progression or toxicity (TTF), and overall survival (OS) since the 1st dose of P. There were statistically significant differences in 1st line TTF and OS between MSKCC subgroups. Conclusions: In p with mRC and good-intermediate prognosis, P appears to be as effective in daily clinical practice as it was in 1st line trials. P also showed efficacy in p with poor risk, in 2nd-line (particularly progression or intolerance to sunitinib), and after 2 or more TKIs. Updated analysis will be available in June 2013. [Table: see text]